GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

Q2 results 2026

#	Наименование новости	Информативность	Дата публикации
1	GSK delivers strong Q1 performance and start to 2026	20.83	29-04-2026
2	GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers	13.06	12-04-2026
3	GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data	9.57	01-09-2026
4	GSK delivers strong 2025 performance and re-affirms long-term outlooks	30.62	04-02-2026
5	GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK	12.94	28-07-2026
6	GSK presents latest respiratory research to advance patient care at ATS 2026	14.1	06-05-2026
7	GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology	7.12	19-11-2025
8	GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer	16.35	14-09-2026
9	GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B	19.82	07-01-2026
10	GSK presents data from its advancing liver pipeline at AASLD 2025	14.22	07-11-2025

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 19.07. Источник: www.gsk.com.

Найдите то, что Вас интересует